1. Combination Antihypertensive Therapy Prescribing and Blood Pressure Control in a Real-World Setting
- Author
-
Yan Gong, Caitrin W. McDonough, Rhonda M. Cooper-DeHoff, Julie A. Johnson, Oyunbileg Magvanjav, and William R. Hogan
- Subjects
Adult ,Male ,medicine.medical_specialty ,Combination therapy ,medicine.drug_class ,Original Contributions ,Blood Pressure ,030204 cardiovascular system & hematology ,Drug Prescriptions ,03 medical and health sciences ,0302 clinical medicine ,Diabetes mellitus ,Internal medicine ,Internal Medicine ,Electronic Health Records ,Humans ,Medicine ,030212 general & internal medicine ,Myocardial infarction ,Practice Patterns, Physicians' ,Antihypertensive drug ,Antihypertensive Agents ,Aged ,business.industry ,Middle Aged ,medicine.disease ,Drug Utilization ,Treatment Outcome ,Drug class ,Blood pressure ,Concomitant ,Hypertension ,Ambulatory ,Drug Therapy, Combination ,Female ,business - Abstract
BACKGROUND Specific combinations of two drug classes are recommended in a variety of clinical situations in the management of hypertension. These preferred combinations are based on complimentary blood pressure (BP) lowering mechanisms or benefit for a concomitant disease. METHODS Using electronic health records (EHRs) data from 27,579 ambulatory hypertensive patients, we investigated antihypertensive therapy prescribing patterns and associations of preferred two drug classes with BP control. RESULTS Overall, BP control, defined as BP CONCLUSIONS Prescribing of guideline-recommended antihypertensive drug classes for concomitant diseases is suboptimal and prescribing of preferred/optimized drug class combinations was moderate. We did not find a clear association between the use of optimized drug class combinations and greater BP control. Overall, using EHR data, we identified potential opportunities for re-examining prescribing practices with implications for clinical decision support and healthcare improvement at the community and health system-wide levels.
- Published
- 2019